| 摘要 |
The present invention provides methods for treating individuals having an HCV infection, which individuals have failed to respond to therapy with an INF-alpha other than consensus interferon (CIFN), or who, following cessation of therapy with an INF-alpha other than CIFN, have suffered relapse. The methods generally involve a dosage regimen involving administering a dose of CIFN and a dose of ribavirin for a period of time, where the dosage regimen is effective to achieve a sustained viral response in the individual.
|
